Balyasny Asset Management LLC Allogene Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.23 - $4.38 $72,040 - $141,495	32,305 Added 151.55%	53,622 $124,000
Q1 2024 May 13, 2024	BUY	$2.92 - $5.63 $16,314 - $31,454	5,587 Added 35.52%	21,317 $95,000
Q4 2023 Feb 14, 2024	BUY	$2.28 - $3.5 $35,864 - $55,055	15,730 New	15,730 $50,000
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $713,228 - $1.41 Million	126,909 Added 305.96%	168,388 $1.06 Million
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $428,063 - $716,757	41,479 New	41,479 $448,000
Q2 2021 Aug 16, 2021	SELL	$23.49 - $35.8 $2.31 Million - $3.52 Million	-98,208 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$25.79 - $39.02 $2.53 Million - $3.83 Million	98,208 New	98,208 $3.47 Million
Q4 2020 Feb 16, 2021	SELL	$25.24 - $43.45 $3.71 Million - $6.39 Million	-147,059 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$32.38 - $44.96 $4.76 Million - $6.61 Million	147,059 New	147,059 $5.55 Million

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.